| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/29/2010 | WO2009131553A3 Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| 04/29/2010 | WO2009117277A3 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| 04/29/2010 | WO2008146911A9 Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody |
| 04/29/2010 | US20100105865 Nucleic acids and proteins from streptococcus groups a & b |
| 04/29/2010 | US20100105151 Novel Druggable Regions in the Dengue Virus Envelope Glycoprotein and Methods of Using the Same |
| 04/29/2010 | US20100105121 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 04/29/2010 | US20100105107 Purification and characterization of soluble mhc proteins |
| 04/29/2010 | US20100104632 Drug Having Regulatory Cell Ligand Contained in Liposome |
| 04/29/2010 | US20100104629 Cationic lipids and uses thereof |
| 04/29/2010 | US20100104606 Allergen fragments |
| 04/29/2010 | US20100104605 Method for preventing and treating influenza |
| 04/29/2010 | US20100104604 Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| 04/29/2010 | US20100104603 Use of staphylococcal superantigen-like protein 5 (ssl5) in medicine |
| 04/29/2010 | US20100104602 Neurotoxin therapy for postprandial hyperglycemia |
| 04/29/2010 | US20100104601 Treatment of immune disease by mucosal delivery of antigents using genetically modified lactobacillus |
| 04/29/2010 | US20100104600 Methods and Compositions for Increasing Tissue Tropism of Recombinant Adenoviral Vectors |
| 04/29/2010 | US20100104599 Compositions and Methods For Enhancing Immune System of Felines |
| 04/29/2010 | US20100104598 Development of dengue virus vaccine components |
| 04/29/2010 | US20100104597 N-linked glycosylation alteration in E0 and E2 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine |
| 04/29/2010 | US20100104596 Acutte transmitted hiv envelope signatures |
| 04/29/2010 | US20100104595 Lyophilized preparation comprising influenza vaccine, and method for preparation thereof |
| 04/29/2010 | US20100104594 Pathogen for bacterial poultry disease |
| 04/29/2010 | US20100104593 Meningococcal conjugate vaccination |
| 04/29/2010 | US20100104592 Hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 04/29/2010 | US20100104591 Polypeptides for inducing a protective immune response against staphylococcus epidermidis |
| 04/29/2010 | US20100104590 Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient |
| 04/29/2010 | US20100104589 Immunoconjugates with an Intracellularly-Cleavable Linkage |
| 04/29/2010 | US20100104588 Serum albumin binding peptides for tumor targeting |
| 04/29/2010 | US20100104587 Methods of modulating the negative chemotaxis of immune cells |
| 04/29/2010 | US20100104586 Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors |
| 04/29/2010 | US20100104585 Methods and Reagents for Regulation of Cellular Responses in Biological Systems |
| 04/29/2010 | US20100104584 Genes involved in mitochondrial biogenesis |
| 04/29/2010 | US20100104583 Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy |
| 04/29/2010 | US20100104582 CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts |
| 04/29/2010 | US20100104581 Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions |
| 04/29/2010 | US20100104580 Altered Immunogenic Landscape in HIV-1 Envelope Proteins |
| 04/29/2010 | US20100104579 Trex1 as a marker for lupus erythematosus |
| 04/29/2010 | US20100104578 Method and composition for treatment of neoplasms |
| 04/29/2010 | US20100104577 Methods and materials related to anti-a (beta) antibodies |
| 04/29/2010 | US20100104576 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response; immunization; |
| 04/29/2010 | US20100104575 Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| 04/29/2010 | US20100104574 Frizzled-Binding Agents and Uses Thereof |
| 04/29/2010 | US20100104573 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| 04/29/2010 | US20100104572 Methods for screening for therapeutic molecules and use of the molecules therefrom |
| 04/29/2010 | US20100104571 Antibody-mediated modulation of allergy |
| 04/29/2010 | US20100104570 Semaphorin 7A Plays a Critical Role in TGF-Beta1-Induced Pulmonary Fibrosis and Alveolar Destruction |
| 04/29/2010 | US20100104569 Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
| 04/29/2010 | US20100104568 Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| 04/29/2010 | US20100104567 Pharmaceutical composition |
| 04/29/2010 | US20100104566 Antitumor combination comprising a morpholinyl anthracycline and an antibody |
| 04/29/2010 | US20100104565 Combinations comprising dmxaa for the treatment of cancer |
| 04/29/2010 | US20100104564 Altered Antibody Fc Regions and Uses Thereof |
| 04/29/2010 | US20100104563 Interleukin-18 specific immunoglobulins for treatment and prevention of autoimmune, respiratory, reproductive, heart, connective tissue, liver, bone and arthritic disorders |
| 04/29/2010 | US20100104562 Enhancing Efficacy of Vaccines Administered Via the Respiratory Tract |
| 04/29/2010 | US20100104561 TYROSINE-MODIFIED RECOMBINANT rAAV VECTOR COMPOSITIONS AND METHODS FOR USE |
| 04/29/2010 | US20100104560 Botulinum neurotoxin e receptors and uses thereof |
| 04/29/2010 | US20100104559 Us cip-compositions and methods for modulating responses mediated or associated with btla activity |
| 04/29/2010 | US20100104558 Use of an EGFR Antagonist for the Treatment of Glomerolonephritis |
| 04/29/2010 | US20100104557 Optimized Antibodies that Target HM1.24 |
| 04/29/2010 | US20100104556 Epitope-tag for surface-expressed proteins and uses thereof |
| 04/29/2010 | US20100104555 HCV neutralizing epitopes |
| 04/29/2010 | US20100104554 Peptide and uses thereof |
| 04/29/2010 | US20100104553 Antibodies and methods for making and using them |
| 04/29/2010 | US20100104531 Homogeneous preparations of il-28 and il-29 |
| 04/29/2010 | US20100104530 Anti-vpac1 antibodies and their uses |
| 04/29/2010 | US20100104510 Selenocysteine mediated hybrid antibody molecules |
| 04/29/2010 | US20100104509 Human antibodies that bind cd19 and uses thereof |
| 04/29/2010 | US20100104508 Human antibodies that bind cxcr4 and uses thereof |
| 04/29/2010 | US20100104507 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
| 04/29/2010 | US20100104503 Modular nanoparticles for adaptable vaccines |
| 04/29/2010 | CA2741619A1 Vaccine compositions comprising a mutated factor h binding protein |
| 04/29/2010 | CA2741553A1 Methods for determining the levels of tgf-.beta. in a composition |
| 04/29/2010 | CA2741523A1 Human ebola virus species and compositions and methods thereof |
| 04/29/2010 | CA2741489A1 Methods, compositions, and kits for diagnosing, monitoring, and treating disease |
| 04/29/2010 | CA2741435A1 Immunization protocol for directed expansion and maturation |
| 04/29/2010 | CA2741419A1 Anti-fmd vaccine composition and preparation and use thereof |
| 04/29/2010 | CA2741399A1 Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| 04/29/2010 | CA2741396A1 Combination vaccine with acellular pertussis |
| 04/29/2010 | CA2741393A1 Combination vaccine with whole cell pertussis |
| 04/29/2010 | CA2741333A1 Vaccine against african horse sickness virus |
| 04/29/2010 | CA2741291A1 Lipidated imidazoquinoline derivatives |
| 04/29/2010 | CA2741089A1 Modulation of axon degeneration |
| 04/29/2010 | CA2740857A1 Composition for targeting dendritic cells |
| 04/29/2010 | CA2674454A1 Improved hcv vaccines and methods for using the same |
| 04/28/2010 | EP2180323A1 Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin A complexes in a blood sample |
| 04/28/2010 | EP2180054A1 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 04/28/2010 | EP2180044A1 Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| 04/28/2010 | EP2180041A2 New lines of human hepatomas, methods for obtaining same and applications thereof |
| 04/28/2010 | EP2180007A2 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 04/28/2010 | EP2179745A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 04/28/2010 | EP2179744A1 Decreasing potential latrogenic risks associated with influenza vaccines |
| 04/28/2010 | EP2179742A1 Compositions and methods for the treatment of immune related diseases |
| 04/28/2010 | EP2179729A1 Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| 04/28/2010 | EP2179039A2 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 04/28/2010 | EP2178920A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/28/2010 | EP2178919A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/28/2010 | EP2178918A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/28/2010 | EP2178916A1 Human antibodies to human cd20 and method of using thereof |
| 04/28/2010 | EP2178915A2 Anti cd37 antibodies |
| 04/28/2010 | EP2178567A2 Stabilized immune modulatory rna (simra) compounds |